PATENT CLAIM ANALYSIS

Application Number: 16192274
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "004400"]

Abstract:
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

Claim (Index 172):
The method of  claim 164 , wherein the anti-tumor response comprises a T-cell response.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 98.0
- Lexical Diversity: 1.55319
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15996146', '15995889', '16184282', '16002376', '16002472']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8692653564559684
- 35 USC 102 Novelty (BERT): 0.6248446899177411
- Combined Prediction Score: 0.8448232898021456
- Mean Citation Score: 642.8568
- Max Citation Score: 880.4875
- Similarity Product: 504.0634459719062

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test